EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events.
Phase of Trial: Phase III
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Cinacalcet (Primary)
- Indications Cardiovascular disorders; Heart failure; Secondary hyperparathyroidism
- Focus Registrational; Therapeutic Use
- Acronyms EVOLVE
- Sponsors Amgen
- 11 Jun 2015 Results of post hoc analysis have been published in the Circulation.
- 04 Jun 2015 Results published in the Journal of Human Hypertension.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.